{"id":62794,"date":"2024-12-17T00:01:11","date_gmt":"2024-12-17T00:01:11","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/12\/17\/quipt-home-medical-reports-fourth-quarter-and-fiscal-year-2024-financial-results\/"},"modified":"2024-12-17T00:01:11","modified_gmt":"2024-12-17T00:01:11","slug":"quipt-home-medical-reports-fourth-quarter-and-fiscal-year-2024-financial-results","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/quipt-home-medical-reports-fourth-quarter-and-fiscal-year-2024-financial-results\/","title":{"rendered":"Quipt Home Medical Reports Fourth Quarter and Fiscal Year 2024 Financial Results"},"content":{"rendered":"<div>\n<p align=\"center\"><strong>Posts Strong Adjusted EBITDA Margin<\/strong>\u200e<sup><strong>1<\/strong><\/sup> \u200e<strong>for Fiscal Year 2024 and Returns to Positive Sequential Growth in Fiscal Q4 2024<\/strong><\/p>\n<p align=\"justify\">CINCINNATI, Dec.  16, 2024  (GLOBE NEWSWIRE) &#8212; Quipt Home Medical Corp. (\u201c<strong>Quipt<\/strong>\u201d or the \u201c<strong>Company<\/strong>\u201d) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced its fourth quarter and fiscal year 2024 financial results and operational highlights. These results pertain to the three months and year ended September\u00a030, 2024 and are reported in U.S. Dollars.<\/p>\n<p align=\"justify\">The Company no longer qualifies as a \u201cforeign private issuer\u201d as such term is defined in Rule 405 under the U.S. Securities Act of 1933, as amended, and Rule 3b-4 under the Securities Exchange Act of 1934, as amended (the \u201cExchange Act\u201d), which means that the Company, as of October 1, 2024, has been required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers. Accordingly, the Company is now required to prepare its financial statements filed with the Securities and Exchange Commission (\u201c<strong>SEC<\/strong>\u201d) in accordance with generally accepted accounting principles in the United States (\u201c<strong>U.S. GAAP<\/strong>\u201d), starting with the Company\u2019s fourth quarter and full year fiscal 2024 results.<\/p>\n<p align=\"justify\">In addition, as required pursuant to section 4.3(4) of National Instrument 51-102 &#8211; <em>Continuous Disclosure Obligations<\/em>, the Company must restate and file under the Company&#8217;s profile on SEDAR+ (www.sedarplus.com), \u200eits interim financial reports for the fiscal year ended September 30, 2024 in accordance with U.S. GAAP, such interim financial reports having previously been prepared in accordance with the International Financial Reporting Standards (\u201c<strong>IFRS<\/strong>\u201d).<\/p>\n<p align=\"justify\"><strong><u>Conference Call<\/u><\/strong><\/p>\n<p align=\"justify\">Quipt will host its Earnings Conference Call on Tuesday, December 17, 2024 at 10:00 a.m. (ET). Interested parties may participate in the call by dialing:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:10pt; text-align:justify;\">+1 (844) 763-8274, or<\/li>\n<li style=\"margin-bottom:10pt; text-align:justify;\">+1 (647) 484-8814.<\/li>\n<\/ul>\n<p align=\"justify\">The live audio webcast can be found on the investor section of the Company\u2019s website through the following link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kinjDEnElwzLhhGheNbgw0FNTokmw8EUFWRlW8hcxugu3Eqo1UOhYzQ6gttGAHS_y4Vme8Do3eAVbByXUk0UxqVgltufruBndhYPwMxD7ug=\" rel=\"nofollow\" target=\"_blank\" title=\"www.quipthomemedical.com\">www.quipthomemedical.com<\/a>.<\/p>\n<p align=\"justify\">Following the conclusion of the call, a replay of the webcast will be available on the Company\u2019s website for at least the first year following the event.<\/p>\n<p align=\"justify\"><strong><u>Financial Highlights<\/u><\/strong><strong>:<\/strong><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:10pt; text-align:justify;\">Revenue for fiscal year 2024 was $245.9 million compared to $211.7 million for fiscal year 2023, representing a 16.2% increase. Organic Growth<sup>1<\/sup> was approximately $7.1 million, or 3%.\n<ul type=\"circle\">\n<li style=\"margin-bottom:10pt; text-align:justify;\">The transition from IFRS to U.S. GAAP resulted in a reduction of revenues for fiscal year 2023 of $10.1 million with a corresponding elimination of bad debt expense, resulting in no change to Adjusted EBITDA<sup>1<\/sup> or net loss. The comparison periods reflect this change.<\/li>\n<li style=\"margin-bottom:10pt; text-align:justify;\">The pause of the Medicare 75\/25 relief as of January 1, 2024, and the withdrawal of Medicare Advantage members due to the capitated agreement engaged with other providers in the industry negatively impacted revenue by approximately $5 million for fiscal year 2024. Moreover, the estimated impact on the cash collections of accounts receivable from the February 21, 2024 cyberattack on Change Healthcare is estimated at approximately $3 million.<\/li>\n<\/ul>\n<\/li>\n<li style=\"margin-bottom:10pt; text-align:justify;\">Recurring Revenue\u200e<sup>1<\/sup> for fiscal year 2024 was very strong and was approximately 78% of total revenue, driven by the growth in the Company\u2019s re-supply platform.<\/li>\n<li style=\"margin-bottom:10pt; text-align:justify;\">Adjusted EBITDA for fiscal year 2024 was $57.9 million (23.5% margin), compared to Adjusted EBITDA for fiscal year 2023 of $50.6 million (23.9% margin), representing a 14.3% increase.<\/li>\n<li style=\"margin-bottom:10pt; text-align:justify;\">Net income (loss) for fiscal year 2024 was ($6.8) million, or ($0.16) per diluted share, compared to ($2.8) million, or ($0.07) per diluted share for fiscal year 2023.<\/li>\n<li style=\"margin-bottom:10pt; text-align:justify;\">Revenue for Q4 2024 was $61.3 million compared to $59.6 million for Q4 2023, representing a 3% increase. Sequential organic revenue growth was approximately 1%.<\/li>\n<li style=\"text-align:justify;\">Adjusted EBITDA for Q4 2024 was $13.4 million (21.8% margin) compared to $14.7 million (24.6% margin) for Q4 2023, representing an 8.8% decrease.<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"margin-bottom:10pt; text-align:justify;\">Cash flow from operations was $35.4 million for fiscal year 2024, compared to $37 million for fiscal year 2023.<\/li>\n<li style=\"margin-bottom:10pt; text-align:justify;\">The Company reported $16.2 million of cash on hand as of September 30, 2024, compared to $14.4 million as of June 30, 2024. Total credit availability of $34.7 million as of September\u00a030, 2024 with $13.7 million available towards a revolving credit facility and $21 million available pursuant to a delayed-draw term loan facility.<\/li>\n<li style=\"text-align:justify;\">The Company maintains a conservative balance sheet with Net Debt to Adjusted EBITDA Leverage Ratio<sup>1<\/sup> of 1.6x.<\/li>\n<\/ul>\n<p align=\"justify\"><strong><u>Operational Highlights<\/u><\/strong><strong>:<\/strong><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:10pt; text-align:justify;\">The Company\u2019s customer base increased 4% year over year to approximately 153,000 unique patients served in Q4 2024 from approximately 147,000 unique patients in Q4 2023.<\/li>\n<li style=\"margin-bottom:10pt; text-align:justify;\">Compared to approximately 754,000 unique set-ups\/deliveries in fiscal year 2023, the Company completed approximately 854,000 unique set-ups\/deliveries in fiscal year 2024, an increase of 13%. This includes approximately 480,000 respiratory resupply set-ups\/deliveries for fiscal year 2024, compared to approximately 396,000 for fiscal year 2023, an increase of 21%, which the Company credits to its continued use of technology and centralized intake processes.<\/li>\n<li style=\"margin-bottom:10pt; text-align:justify;\">The Company\u2019s resupply program is a major proponent of the 78% Recurring Revenue base as the Company has significantly scaled, now representing 51%, of the Recurring Revenue mix, driving higher margin revenue and now consists of 172,000 patients as of September 30, 2024, compared to 169,000 patients as of September 30, 2023.<\/li>\n<li style=\"margin-bottom:10pt; text-align:justify;\">Positive sequential organic revenue growth of 1% in Q4 2024, signaling a gradual recovery from challenges faced throughout the year.<\/li>\n<li style=\"margin-bottom:10pt; text-align:justify;\">Consistent demand and referral patterns across all major product categories.<\/li>\n<li style=\"text-align:justify;\">The Company has approximately 314,000 unique active patients that were served at least once in the last \u200etwelve months, approximately 36,000 referring physicians, and approximately 135 locations.\u200e<\/li>\n<\/ul>\n<p align=\"justify\"><strong><u>Management Commentary<\/u><\/strong><strong>:<\/strong><\/p>\n<p align=\"justify\">\u201cOur results for fiscal 2024 reflect the resilience of our business and the scalability of our operating model,\u201d said Gregory Crawford, Chairman and CEO of Quipt. \u201cDespite facing unique challenges this year, we delivered record revenue, positive year-over-year organic growth and maintained a strong Adjusted EBITDA Margin<sup>1<\/sup>. This performance underscores the strength of our diversified product offering, go-to-market strategy and the adaptability of our team.<\/p>\n<p align=\"justify\">As we look ahead to calendar 2025 and beyond, we have a high confidence level in our ability to return to consistent, historical organic growth levels. Our focus remains on leveraging the demographic trends such as the aging population and increasing prevalence of chronic respiratory conditions, while expanding our referral base through our growing salesforce and strategic investments. By combining these initiatives with our disciplined approach to inorganic growth, we aim to strengthen our market position and deliver sustained growth.<\/p>\n<p align=\"justify\">The demand for in-home respiratory solutions continues to grow, and our ability to provide comprehensive, patient-centric care positions us well to capture this opportunity. We remain committed to operational excellence, enhancing our recurring revenue base, and executing on our growth roadmap to drive both scale and profitability. With a strong balance sheet, we are well-equipped to allocate capital toward strategic opportunities, while also investing in organic growth to build long-term shareholder value.\u201d<\/p>\n<p align=\"justify\">\u201cOur financial performance in fiscal 2024 highlights the stability of our core operations,\u201d added Hardik Mehta, Chief Financial Officer of Quipt. \u201cIn the fourth quarter, we returned to positive sequential organic revenue growth, which demonstrates the regained momentum in our business. As we move into calendar 2025, we are seeing strengthening trends across our major product categories, supported by solid referral activity and steady demand for our end-to-end respiratory care solutions. These factors give us confidence that we will return to consistent, historical organic growth levels in calendar 2025. With a scalable operating model, a focused growth strategy, and favorable demographic tailwinds, we are well-positioned to seize the opportunities in front of us.\u201d<\/p>\n<p><strong>ABOUT QUIPT HOME MEDICAL CORP.<\/strong><\/p>\n<p align=\"justify\">The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company\u2019s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient\u2019s services, and making life easier for the patient.<\/p>\n<p align=\"justify\"><em>Forward-Looking Statements<\/em><\/p>\n<p align=\"justify\"><em>Certain statements contained in this press release constitute \u201cforward-looking statements\u201d within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or &#8220;forward-looking information&#8221; as such term is \u200e\u200e\u200e\u200e\u200e\u200edefined in applicable Canadian securities legislation (collectively, \u201cforward-looking statements\u201d). The words &#8220;may&#8221;, &#8220;would&#8221;, &#8220;could&#8221;, &#8220;should&#8221;, &#8220;potential&#8221;, \u200e\u200e\u200e\u200e\u200e\u200e\u200e&#8221;will&#8221;, &#8220;seek&#8221;, &#8220;intend&#8221;, &#8220;plan&#8221;, &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;estimate&#8221;, &#8220;expect&#8221;, &#8220;outlook&#8221;, or the negatives thereof or variations of such words, and similar expressions \u200e\u200e\u200e\u200e\u200eas \u200ethey relate to the Company, including: the Company anticipating a return to historical organic growth levels; are intended to \u200eidentify forward-looking information. All statements \u200eother \u200ethan \u200estatements of \u200e\u200ehistorical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-\u200elooking statements<\/em> <em>and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the \u200eCompany&#8217;s \u200ecurrent \u200eviews and \u200e\u200eintentions with respect to future \u200eevents, and current information available to the \u200eCompany, and \u200eare \u200esubject to \u200e\u200ecertain risks, uncertainties and \u200eassumptions, including, without limitation: the \u200eCompany successfully identifying, \u200e\u200e\u200enegotiating and \u200ecompleting additional acquisitions; operating and other financial metrics maintaining their \u200e\u200ecurrent trajectories, the Company not being impacted by any further external and unique events like the Medicare \u200e\u200e75\/25 rate cut and the Change Healthcare cybersecurity incident for the remainder of the calendar year and in 2025; and the \u200eCompany not being subject to a material change to it cost structure. Many \u200efactors could cause the actual \u200eresults, \u200e\u200eperformance or achievements that may be \u200eexpressed \u200eor implied by such \u200eforward-looking statements to \u200evary from \u200e\u200ethose described herein should one or more \u200eof these \u200erisks or \u200euncertainties materialize. Examples of such \u200erisk \u200efactors \u200einclude, without limitation: risks related \u200eto credit, market \u200e\u200e\u200e(including equity, commodity, foreign exchange \u200eand interest \u200erate), \u200eliquidity, operational \u200e\u200e(including technology \u200eand \u200einfrastructure), reputational, insurance, \u200estrategic, \u200eregulatory, legal, \u200eenvironmental, and \u200ecapital adequacy; the \u200e\u200egeneral business and economic conditions in \u200ethe regions \u200ein which the \u200eCompany operates; \u200ethe ability of the \u200e\u200eCompany to execute on key priorities, including the \u200esuccessful \u200ecompletion of \u200eacquisitions, \u200ebusiness retention, and \u200e\u200estrategic plans and to attract, develop and retain \u200ekey \u200eexecutives; difficulty \u200eintegrating \u200enewly acquired businesses; \u200e\u200ethe ability to implement business strategies and \u200e\u200epursue business opportunities; low \u200eprofit \u200emarket segments; \u200e\u200edisruptions in or attacks (including cyber-attacks) on \u200e\u200ethe Company&#8217;s information \u200etechnology, \u200einternet, network \u200e\u200eaccess or other voice or data communications systems or \u200e\u200eservices; the evolution of \u200evarious types \u200eof fraud or other \u200e\u200ecriminal behavior to which the Company is exposed; the \u200e\u200efailure of third parties to \u200ecomply with \u200etheir obligations to \u200e\u200ethe Company or its affiliates; the impact of new and \u200e\u200echanges to, or application of, \u200ecurrent \u200elaws and regulations; \u200e\u200edecline of reimbursement rates; dependence on few \u200e\u200epayors; possible new drug \u200ediscoveries; a \u200enovel business \u200emodel; \u200edependence on key suppliers; granting of permits \u200e\u200eand licenses in a highly \u200eregulated \u200ebusiness; legal proceedings and litigation, including as it relates to the civil \u200e\u200einvestigative demand (\u201cCID\u201d) \u200ereceived from the Department of Justice; \u200eincreased competition; \u200echanges in \u200eforeign currency rates; \u200eincreased \u200e\u200efunding costs and market volatility due to \u200emarket illiquidity and \u200ecompetition for \u200efunding; the \u200eavailability of funds \u200e\u200eand resources to pursue operations; \u200ecritical accounting \u200eestimates and changes \u200eto accounting \u200estandards, policies, \u200e\u200eand methods used by the Company; the Company\u2019s status as an emerging growth company and a smaller reporting company; the occurrence of \u200enatural and unnatural \u200ecatastrophic \u200eevents or health epidemics or concerns; as well as those risk factors \u200ediscussed or \u200e\u200ereferred to \u200ein the Company\u2019s disclosure \u200edocuments filed with \u200eUnited States Securities and Exchange \u200eCommission \u200e\u200e(the \u201cSEC\u201d) and \u200eavailable at www.sec.gov, including the Company\u2019s most recent Annual Report on Form 10-K, and with \u200ethe securities \u200eregulatory authorities in certain provinces of \u200eCanada and \u200e\u200e\u200eavailable at www.sedarplus.com. Should any \u200efactor affect \u200ethe Company in an unexpected manner, or \u200eshould \u200e\u200e\u200eassumptions underlying the forward-looking \u200estatement prove \u200eincorrect, the actual results or events may \u200ediffer \u200e\u200e\u200ematerially from the results or events predicted. \u200eAny such forward-\u200elooking statements are expressly qualified \u200ein their \u200e\u200e\u200eentirety by this cautionary statement. Moreover, \u200ethe Company \u200edoes not assume responsibility for the \u200eaccuracy or \u200e\u200e\u200ecompleteness of such forward-looking \u200estatements. The \u200eforward-looking statements included in this \u200epress release \u200e\u200e\u200eis made as of the date of this press \u200erelease and the \u200eCompany undertakes no obligation to publicly \u200eupdate or revise \u200e\u200e\u200eany forward-looking statements, \u200eother than as \u200erequired by applicable law\u200e.\u200e<\/em><\/p>\n<p align=\"justify\"><em>Non-GAAP Financial Measures<\/em><\/p>\n<p align=\"justify\"><em>This press release refers to \u201cOrganic Growth\u201d, \u201cRecurring Revenue\u201d, \u201cAdjusted EBITDA\u201d, \u201cAdjusted EBITDA Margin\u201d and \u201cAdjusted Net Debt to Adjusted EBITDA Leverage Ratio\u201d, which are non-GAAP financial measures that do not have standardized meanings prescribed by U.S. GAAP. The \u200eCompany\u2019s presentation of these financial measures may not be comparable to similarly titled measures used by \u200eother companies. These financial measures are intended to provide additional information to investors concerning \u200ethe Company\u2019s performance.\u200e<\/em><\/p>\n<p align=\"justify\"><em>Organic Growth is calculated as the increase in revenues of $34.2 million, less the revenues contributed by acquisitions of $27.1 million, divided by fiscal year 2023 revenue of $211.7 million, or 3%.<\/em><\/p>\n<p align=\"justify\"><em>Recurring Revenue for fiscal 2024 is calculated as rentals of medical equipment of $94.3 million plus sales of respiratory resupplies of $96.5 million for a total of $190.8 million, divided by total revenues of $245.9 million, or 78%.<\/em><\/p>\n<p align=\"justify\"><em>Adjusted EBITDA is calculated as net loss, and adding back depreciation and amortization, right-of-use operating lease amortization and interest, interest expense, net, provision (benefit) for income taxes, professional fees related to civil investigative demand and loss of foreign private issuer status, stock-based compensation, acquisition-related costs, loss on extinguishment of debt, gain (loss) on foreign currency transactions, change in fair value of derivative liability \u2013 interest rate swap, and share of loss of equity method investment. The following table shows our non-GAAP measure, Adjusted EBITDA, reconciled to our net income (loss) for the \u200efollowing indicated periods\u200e (in $millions)\u200e:\u200e<\/em><\/p>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"3\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><em>For the three<\/em><\/td>\n<td style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"3\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><em>For the three<\/em><\/td>\n<td style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"3\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><em>For the<\/em><\/td>\n<td style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"3\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><em>For\u00a0the<\/em><\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"3\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><em>months ended<\/em><\/td>\n<td style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"3\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><em>months ended<\/em><\/td>\n<td style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"3\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><em>year ended<\/em><\/td>\n<td style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"3\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><em>year ended<\/em><\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"3\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><em>September<\/em><\/td>\n<td style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"3\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><em>September<\/em><\/td>\n<td style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"3\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><em>September<\/em><\/td>\n<td style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"3\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><em>September<\/em><\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"3\" style=\"border-bottom: solid black 1pt ; padding-right: 0 ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><em>30,\u00a02024<\/em><\/td>\n<td style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"3\" style=\"border-bottom: solid black 1pt ; padding-right: 0 ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><em>30,\u00a02023<\/em><\/td>\n<td style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"3\" style=\"border-bottom: solid black 1pt ; padding-right: 0 ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><em>30,\u00a02024<\/em><\/td>\n<td style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"3\" style=\"border-bottom: solid black 1pt ; padding-right: 0 ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><em>30,\u00a02023<\/em><\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:45%; width:45%; min-width:45%;;text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \"><em>Net loss<\/em><\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \"><em>$<\/em><\/td>\n<td style=\"max-width:11%; width:11%; min-width:11%;;padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>(3.2<\/em><\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \"><em>)<\/em><\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \"><em>$<\/em><\/td>\n<td style=\"max-width:11%; width:11%; min-width:11%;;padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>(1.3<\/em><\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \"><em>)<\/em><\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \"><em>$<\/em><\/td>\n<td style=\"max-width:11%; width:11%; min-width:11%;;padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>(6.8<\/em><\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \"><em>)<\/em><\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \"><em>$<\/em><\/td>\n<td style=\"max-width:11%; width:11%; min-width:11%;;padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>(2.8<\/em><\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \"><em>)<\/em><\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \"><em>Add back:<\/em><\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \"><em>Depreciation and amortization<\/em><\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>11.5<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>10.9<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>44.6<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>36.1<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \"><em>Right-of-use operating lease amortization and interest<\/em><\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>1.4<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>1.5<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>6.0<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>5.1<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \"><em>Interest expense, net<\/em><\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>1.5<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>1.6<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>6.4<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>5.5<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \"><em>Provision (benefit) for income taxes<\/em><\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>(0.3<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \"><em>)<\/em><\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>0.1<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>0.1<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>0.1<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \"><em>Professional fees related to CID<\/em><\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>0.9<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>\u2014<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>3.1<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>\u2014<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \"><em>Professional fees related to loss of foreign private issuer status<\/em><\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>0.2<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>\u2014<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>0.2<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>\u2014<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \"><em>Stock-based compensation<\/em><\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>0.3<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>1.4<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>2.5<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>5.3<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \"><em>Acquisition-related costs<\/em><\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>0.0<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>0.1<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>0.4<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>1.3<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \"><em>Loss on extinguishment of debt<\/em><\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>\u2014<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>\u2014<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>\u2014<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>0.0<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \"><em>Gain (loss) on foreign currency transactions<\/em><\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>(0.2<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \"><em>)<\/em><\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>0.3<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>(0.0<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \"><em>)<\/em><\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>(0.1<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \"><em>)<\/em><\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \"><em>Change in fair value of derivative liability &#8211; interest rate swap<\/em><\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>1.1<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>\u2014<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>1.1<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>\u2014<\/em><\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \"><em>Share of loss in equity method investment<\/em><\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>0.1<\/em><\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>0.1<\/em><\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>0.3<\/em><\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>0.1<\/em><\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \"><em>Adjusted EBITDA<\/em><\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \"><em>$<\/em><\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>13.4<\/em><\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \"><em>$<\/em><\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>14.7<\/em><\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \"><em>$<\/em><\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>57.9<\/em><\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: bottom ; \"><em>$<\/em><\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>50.6<\/em><\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\"><em>Adjusted EBITDA Margin for fiscal 2024 is calculated as Adjusted EBITDA of $57.9 million divided by revenue of $245.9 million, or 23.5%. Q4 2024 is calculated as Adjusted EBITDA of $13.4 million divided by revenue of $61.3 million, or 21.8%.<\/em><\/p>\n<p align=\"justify\"><em>Net Debt to Adjusted EBITDA Leverage Ratio is calculated as Net Debt, divided by (Adjusted EBITDA for Q4 times four), and is reconciled as follows (in $millions):<\/em><\/p>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"max-width:85%; width:85%; min-width:85%;;vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"max-width:14%; width:14%; min-width:14%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><em>As of and for the<br \/><\/em><em>three months ended<br \/><\/em><em>ended September 30,<br \/><\/em><em>2024<\/em><\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \"><em>Senior credit facility, principal<\/em><\/td>\n<td style=\"vertical-align: bottom ; \"><em>$<\/em><\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>69.2<\/em><\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \"><em>Equipment loans<\/em><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>12.9<\/em><\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \"><em>Lease liabilities<\/em><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>19.2<\/em><\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \"><em>Cash<\/em><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>(16.2<\/em><em>)<\/em><\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \"><em>Net Debt<\/em><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>85.1<\/em><\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \"><em>Adjusted EBITDA for Q4 times four<\/em><\/td>\n<td style=\"vertical-align: bottom ; \"><em>$<\/em><\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>53.6<\/em><\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \"><em>Net Debt to Adjusted EBITDA Leverage Ratio<\/em><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \"><em>1.6x<\/em><\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">For further information please visit our website at www.Quipthomemedical.com, or contact:<\/p>\n<p>Cole Stevens<br \/>VP of Corporate Development<br \/>Quipt Home Medical Corp.<br \/>859-300-6455<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MK7AxiDyTTcbIwQhliEfko3gckng14P2EuwzyrzckxhlAY69PhriJ1AfOo2DUSRyXLt4usZIk9LyvZw2SfPMhR6TcYhsHdTIMKHYrqQT8ag=\" rel=\"nofollow\" target=\"_blank\" title=\"cole.stevens@myquipt.com\">cole.stevens@myquipt.com<\/a><\/p>\n<p>Gregory Crawford<br \/>Chief Executive Officer<br \/>Quipt Home Medical Corp.<br \/>859-300-6455<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MbS4ICVGcUyLLq5xhL3mJdAS05l6Ng3Ofbg6d4sj5UjsD4nceFggS_yRxLgpTvA2AD9j5Yflbhex4KVcjHRIgYNkgYF1OT7yJE6JZxnmIJY=\" rel=\"nofollow\" target=\"_blank\" title=\"investorinfo@myquipt.com\">investorinfo@myquipt.com<\/a><\/u><\/p>\n<p align=\"justify\">\u00a0<\/p>\n<p align=\"justify\"><u>___________________________________<\/u><\/p>\n<p><sup>1<\/sup> Non-GAAP financial measure or ratio. See \u201cNon-GAAP Financial Measures\u201d.\u200e<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ODcyZDVhN2ItZjgzOC00OGE0LWJjMjgtZjdmNmVhYTMwNTdkLTEwOTk1NzM=\/tiny\/Quipt-Home-Medical-Corp-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Posts Strong Adjusted EBITDA Margin\u200e1 \u200efor Fiscal Year 2024 and Returns to Positive Sequential Growth in Fiscal Q4 2024 CINCINNATI, Dec. 16, 2024 (GLOBE NEWSWIRE) &#8212; Quipt Home Medical Corp. (\u201cQuipt\u201d or the \u201cCompany\u201d) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced its fourth quarter [&#8230;]\n","protected":false},"author":1,"featured_media":62795,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-62794","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Quipt Home Medical Reports Fourth Quarter and Fiscal Year 2024 Financial Results - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/quipt-home-medical-reports-fourth-quarter-and-fiscal-year-2024-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Quipt Home Medical Reports Fourth Quarter and Fiscal Year 2024 Financial Results\" \/>\n<meta property=\"og:description\" content=\"Posts Strong Adjusted EBITDA Margin\u200e1 \u200efor Fiscal Year 2024 and Returns to Positive Sequential Growth in Fiscal Q4 2024 CINCINNATI, Dec. 16, 2024\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/quipt-home-medical-reports-fourth-quarter-and-fiscal-year-2024-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-17T00:01:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/12\/Quipt-Home-Medical-Corp-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/quipt-home-medical-reports-fourth-quarter-and-fiscal-year-2024-financial-results\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/quipt-home-medical-reports-fourth-quarter-and-fiscal-year-2024-financial-results\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Quipt Home Medical Reports Fourth Quarter and Fiscal Year 2024 Financial Results\",\"datePublished\":\"2024-12-17T00:01:11+00:00\",\"dateModified\":\"2024-12-17T00:01:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/quipt-home-medical-reports-fourth-quarter-and-fiscal-year-2024-financial-results\/\"},\"wordCount\":2488,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/quipt-home-medical-reports-fourth-quarter-and-fiscal-year-2024-financial-results\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/quipt-home-medical-reports-fourth-quarter-and-fiscal-year-2024-financial-results\/\",\"name\":\"Quipt Home Medical Reports Fourth Quarter and Fiscal Year 2024 Financial Results - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-12-17T00:01:11+00:00\",\"dateModified\":\"2024-12-17T00:01:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/quipt-home-medical-reports-fourth-quarter-and-fiscal-year-2024-financial-results\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/quipt-home-medical-reports-fourth-quarter-and-fiscal-year-2024-financial-results\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/quipt-home-medical-reports-fourth-quarter-and-fiscal-year-2024-financial-results\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Quipt Home Medical Reports Fourth Quarter and Fiscal Year 2024 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Quipt Home Medical Reports Fourth Quarter and Fiscal Year 2024 Financial Results - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/quipt-home-medical-reports-fourth-quarter-and-fiscal-year-2024-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Quipt Home Medical Reports Fourth Quarter and Fiscal Year 2024 Financial Results","og_description":"Posts Strong Adjusted EBITDA Margin\u200e1 \u200efor Fiscal Year 2024 and Returns to Positive Sequential Growth in Fiscal Q4 2024 CINCINNATI, Dec. 16, 2024","og_url":"https:\/\/english.saigonbiz.com\/vn\/quipt-home-medical-reports-fourth-quarter-and-fiscal-year-2024-financial-results\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-12-17T00:01:11+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/12\/Quipt-Home-Medical-Corp-.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/quipt-home-medical-reports-fourth-quarter-and-fiscal-year-2024-financial-results\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/quipt-home-medical-reports-fourth-quarter-and-fiscal-year-2024-financial-results\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Quipt Home Medical Reports Fourth Quarter and Fiscal Year 2024 Financial Results","datePublished":"2024-12-17T00:01:11+00:00","dateModified":"2024-12-17T00:01:11+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/quipt-home-medical-reports-fourth-quarter-and-fiscal-year-2024-financial-results\/"},"wordCount":2488,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/quipt-home-medical-reports-fourth-quarter-and-fiscal-year-2024-financial-results\/","url":"https:\/\/english.saigonbiz.com\/vn\/quipt-home-medical-reports-fourth-quarter-and-fiscal-year-2024-financial-results\/","name":"Quipt Home Medical Reports Fourth Quarter and Fiscal Year 2024 Financial Results - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-12-17T00:01:11+00:00","dateModified":"2024-12-17T00:01:11+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/quipt-home-medical-reports-fourth-quarter-and-fiscal-year-2024-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/quipt-home-medical-reports-fourth-quarter-and-fiscal-year-2024-financial-results\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/quipt-home-medical-reports-fourth-quarter-and-fiscal-year-2024-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Quipt Home Medical Reports Fourth Quarter and Fiscal Year 2024 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/62794","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=62794"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/62794\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/62795"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=62794"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=62794"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=62794"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}